Some Questions to Ask Your Doctor

1. What is a normal PSA level for a person who has received the treatment I've received?

2. How will we monitor PSA changes over time?

3. What happens if my PSA level starts to rise?

4. How will I know if I am at high risk for prostate cancer returning?

5. If I am at high risk for prostate cancer returning, what further testing should I have?

6. What if the prostate cancer progresses or comes back after I receive primary treatment?

Prescribing Information

Print This Page

Send to a Friend

Change Text Size - A A A

Visit the support resources section! Resources for patients including support groups and printable brochures.

Indication and Important Safety Information for CASODEX (bicalutamide) Tablets

CASODEX at a dose of 50 mg daily is a prescription medication approved for use in combination with an injection of a luteinizing hormone-releasing hormone analog (LHRH-A) for treatment of advanced prostate cancer (metastatic Stage D2).

CASODEX at a dose of 150 mg daily is not approved for use alone or with other treatments (see Clinical Studies section 14.2 in the full Prescribing Information ).

There have been reports of liver function problems during treatment with CASODEX. Therefore, your doctor will monitor your liver function with a blood test before you start treatment with CASODEX, at regular intervals during the first 4 months of treatment, and at regular times after that.
Development of diabetes has been reported in men receiving LHRH-As. Therefore, your doctor may monitor your blood sugar during treatment with CASODEX and an LHRH-A.
The most common side effects that occurred during treatment with CASODEX plus an injection of an LHRH-A were hot flashes (53%), pain (21% to 35%, including pelvic, back, and general), weakness (22%), and constipation (22%). Other side effects (reported in 12% to 18% of patients) were urination at night, blood in urine, diarrhea, swelling, shortness of breath, nausea, and infection.

Please click here for full Prescribing Information for CASODEX.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Indications and Important Safety Information for ZOLADEX (goserelin acetate implant)

ZOLADEX 3.6 mg depot and 10.8 mg depot are prescription medications approved for use in combination with flutamide (an antiandrogen) plus radiotherapy for locally advanced prostate cancer. Treatment with the combination should start 8 weeks prior to starting and continue during radiation therapy.

ZOLADEX 3.6 mg depot and 10.8 mg depot are also approved to use alone for patients with advanced prostate cancer. ZOLADEX may help reduce the size of the cancer and reduce symptoms (palliative treatment).

ZOLADEX, like other luteinizing hormone-releasing hormone analogs (LHRH-As), may cause an initial rise in testosterone. When used alone, there may be a temporary worsening of prostate cancer symptoms at the start of therapy.
Development of diabetes has been reported in men receiving LHRH-As like ZOLADEX. Therefore, your doctor may monitor your blood sugar during treatment.
Common side effects that occurred during treatment with ZOLADEX plus flutamide and radiation therapy or ZOLADEX alone included hot flashes, decrease in sexual desire and/or ability to have erections, diarrhea, pain (general, pelvic, and bone), lower urinary tract symptoms, fatigue, nausea, breast growth, swelling, rash, upper respiratory infection, and sweating.

Please click here for full Prescribing Information for ZOLADEX 3.6 mg 1-month Depot.
Please click here for full Prescribing Information for ZOLADEX 10.8 mg 3-month Depot.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

CASODEX and ZOLADEX are registered trademarks of the AstraZeneca group of companies.

This information is intended for US consumers only.

US Corporate Site | Site Map | Contact Us | Privacy Statement | Legal Terms and Conditions